查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750795

多西他賽市場規模、佔有率、趨勢分析報告：按適應症、分銷管道、地區、細分市場預測，2025-2030 年

Docetaxel Market Size, Share & Trends Analysis Report By Indication (Breast Cancer, Non-Small Cell Lung Cancer, Hormone Refractory Prostate Cancer, Gastric Adenocarcinoma), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

多西他賽市場的成長與趨勢

根據 Grand View Research, Inc. 的最新報告，全球多西他賽市場規模預計到 2030 年將達到 18.5 億美元，預測期內的複合年成長率為 5.75%。全球癌症發病率上升推動了多西他賽市場的發展，尤其是乳癌、肺癌和前列腺癌，儘管成長幅度不大，但多西他賽仍然被用作這些疾病的一線或二線治療藥物。雖然由於標靶治療藥物的普及而導致擴張受到限制，但篩檢項目的改進、癌症意識的提高以及對具有成本效益的化療的需求都提高了該藥物的相關性。從 2025 年到 2030 年，乳癌市場預計將以 5.69% 的複合年成長率成長，達到 6.1108 億美元，而荷爾蒙難治性前列腺癌和胃腺癌預計將以中等速度成長。

多西他賽的臨床整合依然強勁。例如，預計到2025年，美國乳癌病例數將超過31.9萬例。早期發現的5年存活率高達99%，篩檢工作支持在轉移性和早期治療中持續使用多西他賽。同樣，非小細胞肺癌 (NSCLC) 和激素抗性前列腺癌的高發生率也支持了持續的需求。隨著學名藥和特殊製劑的推出，市場片段化也加劇。 2025年2月，Zydus Lifesciences與珠海北海生物科技公司簽署了BEIZRAY在美國的商業化協議，BEIZRAY是一種基於白蛋白的多西他賽製劑，將於2024年根據505(b)(2)途徑核准。該藥物的年目標銷售量為53.1萬單位，且不使用合成輔料，因此副作用較少。

此外，研發管線數據顯示組合方案仍在持續發展中。 2027年至2032年，多西他賽與DS-1062a（第一三共）、daraxonlasib（Revolution Medicines）和capivasertib（阿斯特捷利康）等藥物的聯合治療試驗將在非小細胞肺癌、前列腺癌、乳癌和胃癌中進行。這些試驗的贊助商包括諾華、賽諾菲、葛蘭素史克、石藥集團和Mirati，這表明全球公司正在積極參與。

行業趨勢表明，口服多西他賽和緩釋性他賽等給藥方式和劑型正在不斷創新，而生物等效性研究和監管審查等壁壘則阻礙了新進入者。儘管學名藥已上市，但嚴格的標準和根深蒂固的競爭決定了行業格局。總體而言，多西他賽仍然是腫瘤治療方案的核心組成部分，這得益於全球臨床應用、持續的研發管線興趣以及不斷發展的夥伴關係。

多西他賽市場報告重點

  • 從適應症來看，乳癌在多西他賽產業佔據主導地位，佔 2024 年收入佔有率的 33.11%。這種成長可以歸因於全球範圍內的高盛行率、完善的治療方案以及多西他賽在治療中的強大臨床療效。
  • 根據銷售管道，醫院藥局佔據市場主導地位，2024 年的銷售佔有率為 56.00%，這得益於其在管理癌症治療通訊協定和實施化療的核心作用。
  • 主要市場參與者包括 Phyton Biotech LLC、Rochem International Inc.、Alchem International Pvt Ltd、LGM Pharma、HRV Global Life Sciences 等。
  • 2025年2月，諾和諾德宣布美國食品藥物管理局（FDA）宣布非小細胞肺癌 (NSCLC) 和乳癌供不應求結束，確認美國藥物供應已滿足需求。該公司投資65億美元擴大生產，並推出了基於人工智慧的「尋找我的藥物」應用程式。諾和諾德將警告民眾警惕假藥，並強調負責任地使用FDA核准的多西他賽藥物。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 多西他賽市場變數、趨勢和範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

4. 多西他賽市場：適應症業務分析

  • 2024年及2030年的指示市場佔有率
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（2018-2030 年）
  • 乳癌
  • 非小細胞肺癌（NSCLC）
  • 激素抗性前列腺癌
  • 胃腺癌
  • 頭頸部鱗狀細胞癌

5. 多西他賽市場：分銷通路業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

6. 多西他賽市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模與預測趨勢分析：
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Phyton Biotech LLC
    • Rochem International Inc
    • Alchem International Pvt Ltd
    • LGM Pharma
    • HRV Global Life Sciences
    • Tenatra Chemie
    • Teva Active Pharmaceutical Ingredients（TAPI）
    • Arch Pharmalabs
    • Aspen Pharmacare
    • ChemGenix Laboratories Pvt Ltd
    • Cipla Ltd
Product Code: GVR-4-68040-572-6

Docetaxel Market Growth And Trends

The global docetaxel market size is anticipated to reach USD 1.85 billion by 2030, growing at a CAGR of 5.75% during the forecast period, according to a new report by Grand View Research, Inc. Despite moderate growth, the market remains sustained by the rising global cancer burden, particularly in breast, lung, and prostate cancers-diseases where docetaxel continues to be used as a first- or second-line treatment. While the increasing adoption of targeted therapies limits expansion, improved screening programs, heightened cancer awareness, and demand for cost-effective chemotherapy contribute to the drug's relevance. From 2025 to 2030, the breast cancer segment is projected to grow at 5.69% CAGR, reaching USD 611.08 million, while hormone-refractory prostate cancer and gastric adenocarcinoma are forecast to grow at a moderate growth rate.

Clinical integration of docetaxel remains strong. For instance, in 2025, breast cancer cases in the U.S. are expected to surpass 319,000. With a 99% five-year survival when detected early, screening initiatives support consistent docetaxel use in metastatic and early-stage therapies. Similarly, high incidence of non-small cell lung cancer (NSCLC) and hormone-resistant prostate cancer supports sustained demand. Fragmentation is also increasing due to product launches by generics and specialty formulations. In February 2025, Zydus Lifesciences entered a U.S. commercialization agreement with Zhuhai Beihai Biotech for BEIZRAY-an albumin-based docetaxel formulation approved via the 505(b)(2) pathway in 2024. With an annual target volume of \~531,000 units, the drug avoids synthetic excipients to reduce side effects.

Moreover, pipeline data suggest continued development in combination regimens. Between 2027 and 2032, trials involving docetaxel with agents such as DS-1062a (Daiichi Sankyo), daraxonrasib (Revolution Medicines), capivasertib (AstraZeneca), and others target NSCLC, prostate, breast, and gastric cancers. These studies involve sponsors like Novartis, Sanofi, GSK, CSPC, and Mirati, indicating active engagement from global players.

Industry trends show innovation in delivery and formulation, such as oral and extended-release docetaxel, while barriers like bioequivalence testing and regulatory scrutiny moderate new entries. Despite the availability of generics, stringent standards and established competition shape the landscape. Overall, docetaxel remains a core component in oncology protocols, supported by global clinical use, ongoing pipeline interest, and evolving partnerships.

Docetaxel Market Report Highlights:

  • Based on indication, breast cancer dominated the docetaxel industry, accounting for 33.11% of the revenue share in 2024. This growth is driven by high global prevalence, established treatment protocols, and strong clinical efficacy of docetaxel in therapy.
  • Based on distribution channel, hospital pharmacies led the market and accounted for a revenue share of 56.00% in 2024, due to their central role in managing cancer treatment protocols and administering chemotherapy.
  • Key market players include Phyton Biotech LLC, Rochem International Inc., Alchem International Pvt Ltd, LGM Pharma, and HRV Global Life Sciences.
  • In February 2025, Novo Nordisk announced the FDA has declared the Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer shortage over, confirming U.S. supply meets demand. The company invested USD 6.5 billion to expand production and launched the AI-powered Find My Meds app. Novo Nordisk warns against counterfeit drugs and emphasizes responsible use of its FDA-approved docetaxel medicines.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Docetaxel Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Docetaxel Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Breast Cancer
    • 4.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
  • 4.5. Non-Small Cell Lung Cancer (NSCLC)
    • 4.5.1. Non-Small Cell Lung Cancer (NSCLC) Market, 2018 - 2030 (USD Million)
  • 4.6. Hormone Refractory Prostate Cancer
    • 4.6.1. Hormone Refractory Prostate Cancer Market, 2018 - 2030 (USD Million)
  • 4.7. Gastric Adenocarcinoma
    • 4.7.1. Gastric Adenocarcinoma Market, 2018 - 2030 (USD Million)
  • 4.8. Squamous Cell Carcinoma of the Head and Neck
    • 4.8.1. Squamous Cell Carcinoma of the Head and Neck Market, 2018 - 2030 (USD Million)

Chapter 5. Docetaxel Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6. Docetaxel Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Docetaxel Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Docetaxel Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Phyton Biotech LLC
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Rochem International Inc
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Alchem International Pvt Ltd
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. LGM Pharma
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. HRV Global Life Sciences
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Tenatra Chemie
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Teva Active Pharmaceutical Ingredients (TAPI)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Arch Pharmalabs
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Aspen Pharmacare
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. ChemGenix Laboratories Pvt Ltd
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Cipla Ltd
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global docetaxel market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 5 Global docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 North America docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 U.S docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 UK docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 19 UK docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 23 France docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Italy docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Spain docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Spain docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Norway docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Norway docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Denmark docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Japan docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 China docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 40 China docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 India docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 42 India docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Australia docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Australia docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 South Korea docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 46 South Korea docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Thailand docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Latin America docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Brazil docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 55 Argentina docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 60 South Africa docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 UAE docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 64 UAE docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 66 Kuwait docetaxel market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Docetaxel market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Docetaxel market dynamics
  • Fig. 12 Docetaxel market: Porter's five forces analysis
  • Fig. 13 Docetaxel market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Breast Cancer market, 2018 - 2030 (USD Million)
  • Fig. 16 Non-Small Cell Lung Cancer (NSCLC) market, 2018 - 2030 (USD Million)
  • Fig. 17 Hormone Refractory Prostate Cancer market, 2018 - 2030 (USD Million)
  • Fig. 18 Gastric Adenocarcinoma market, 2018 - 2030 (USD Million)
  • Fig. 19 Squamous Cell Carcinoma of the Head and Neck market, 2018 - 2030 (USD Million)
  • Fig. 20 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 21 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 22 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 23 Online Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 24 Docetaxel market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 68 MEA docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework